Phase II study of tauromustine in malignant glioma

A Gregor, R Rampling, M Aapro, P Malmström, I R Whittle, R Rye, M Stewart, R Sellar, B Demierre, J W Ironside

Research output: Contribution to journalArticlepeer-review

Abstract

46 eligible patients with either anaplastic astrocytoma (AA) or glioblastoma (GBM) and clinical and computed-tomography-confirmed relapse following primary surgery and radiotherapy received oral tauromustine 130 mg/m2 every 5 weeks. A prospective design allowed for concurrent assessment of both clinical and radiological responses and drug toxicity. 41% of patients improved clinically whilst 46% improved radiologically with 3 complete, 7 partial and 7 minimal responses (WHO criteria). Toxicity included grade III or IV gastrointestinal side-effects (15%), grade III or IV leukopenia (24%) and grade III and IV thrombocytopenia (44%). In 9 clinically responding patients, haematological toxicity led to discontinuation of treatment. All patients were followed-up until death and second-line chemotherapy was not used. Median post-treatment survival was 26 weeks for patients with GBM and 57 weeks for patients with AA. Overall 2-year survival rate was 69% for AA and 23% for GBM. Tauromustine given at the time of relapse has demonstrable antitumour activity in patients not previously treated with chemotherapy.

Original languageEnglish
Pages (from-to)1959-62
Number of pages4
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume28A
Issue number12
Publication statusPublished - 1992

Keywords

  • Adult
  • Antineoplastic Agents
  • Astrocytoma
  • Brain Neoplasms
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Glioma
  • Humans
  • Leukopenia
  • Male
  • Middle Aged
  • Nausea
  • Nitrosourea Compounds
  • Prospective Studies
  • Taurine
  • Thrombocytopenia

Fingerprint

Dive into the research topics of 'Phase II study of tauromustine in malignant glioma'. Together they form a unique fingerprint.

Cite this